de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

CD20 is a targeted therapy in autoimmune disease treatment, and emerging clinical evidence suggests it may offer a differentiated ... The therapy is currently undergoing Phase I clinical trials for ...

What did this year’s treatment plan look like? On Oct. 8, Idaho State Department of Agriculture staff and partners applied Natrix to the river at a rate of one part per million copper ...

Kabir Nigam [Opens in a new window], Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strategies for ...

But with the silent treatment, you plan to resume communication eventually, even if you yourself don’t know how long the silence will last. It’s “an undefined but temporary period of time,” Suffoletta ...

On October 25, 2024, Prime Minister Ishiba held the 1st Ministerial Meeting on Improving the Treatment and Working Environments and Establishing New Lifetime Career Plans of Self-Defense Forces ...

While Rejoyn is approved for depression, "it is not designed as a standalone treatment," says King; the approval is as a supplement to existing treatments or therapy to improve their effectiveness.

“Particularly in the postpartum period, there’s a lot of anxiety and irritability, plus lack of sleep, which is a huge risk factor for postpartum depression.” And while it’s not necessarily a symptom ...

7 deadline. Step one, track down your 'Annual Notice of Change.' That is the 'heads up' your provider sends out about the upcoming year. The first change you may notice: many Part D plans are ending ...

Tribal leaders with the Jamestown S’Klallam Tribe anticipate starting construction soon on a $31.25 million, 16-bed psychiatric evaluation and treatment facility adjacent to The Jamestown ... “We have ...

HOUSTON — A new breakthrough in depression treatment may soon provide mental health relief from the comfort of your own couch. Researchers have found that a device delivering mild electrical ...

In this Innovation Spotlight, Kevin Fitzgerald, chief scientific officer at Alnylam Pharmaceuticals, discusses the RNAi approach to CVD treatment, recent clinical trial results, and the company’s ...